SUPPLEMENT
Q2 2024 — Financial disclosures
Q2 2024PDF · 10 pages1.1 MB
Merck & Co., Inc. Financial Highlights Package Second Quarter 2024 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 2Q24 and June YTD 24.......3 Table 2b: GAAP to Non-GAAP Reconciliation 2Q23 and June YTD 23.......4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / Ex- U.S. 2Q24........................................................6 Table 3b: Sales – U.S. / Ex- U.S. June YTD 24............................................7 Table 3c: Sales – Pharmaceutical Geographic Split....................................8 Table 4: Other (Income) Expense .............................................................9 -- 1 of 10 -- Sales 15,775 $ 16,112 $ 31,887 $ 14,487 $ 15,035 $ 29,522 $ 15,962 $ 14,630 $ 60,115 $ 7% 8% Costs, Expenses and Other Cost of sales 3,540 3,745 7,285 3,926 4,024 7,951 4,264 3,911 16,126 -7% -8% Selling, general and administrative 2,483 2,739 5,221 2,479 2,702 5,182 2,519 2,804 10,504 1% 1% Research and development 3,992 3,500 7,492 4,276 13,321 17,597 3,307 9,628 30,531 -74% -57% Restructuring costs 123 80 202 67 151 218 126 255 599 -47% -7% Other (income) expense, net (33) 42 12 89 172 259 126 78 466 -76% -95% Income (Loss) Before Taxes 5,670 6,006 11,675 3,650 (5,335) (1,685) 5,620 (2,046) 1,889 * * Income Tax Provision (Benefit) 903 545 1,447 825 637 1,462 870 (821) 1,512 Net Income (Loss) 4,767 5,461 10,228 2,825 (5,972) (3,147) 4,750 (1,225) 377 * * Less: Net Income Attributable to Noncontrolling Interests 5 6 11 4 3 7 5 1 12 Net Income (Loss) Attributable to Merck & Co., Inc. 4,762 $ 5,455 $ 10,217 $ 2,821 $ (5,975) $ (3,154) $ 4,745 $ (1,226) $ 365 $ * * Earnings (Loss) per Common Share Assuming Dilution (1) 1.87 $ 2.14 $ 4.02 $ 1.11 $ (2.35) $ (1.24) $ 1.86 $ (0.48) $ 0.14 $ * * Average Shares Outstanding Assuming Dilution (1) 2,544 2,544 2,544 2,551 2,539 2,539 2,546 2,533 2,547 Tax Rate 15.9% 9.1% 12.4% 22.6% -11.9% -86.8% 15.5% 40.1% 80.0% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. June YTD % Change Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) 2Q (1) Because the company recorded a net loss in the second quarter and first six months of 2023, as well as the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. 2024 2Q June YTD 1Q 1Q 2Q 3Q 4Q Full Year 2023 June YTD 1 -- 2 of 10 -- Sales 16,112 $ 15,035 $ 7% 31,887 $ 29,522 $ 8% Costs, Expenses and Other Cost of sales 3,745 4,024 -7% 7,285 7,951 -8% Selling, general and administrative 2,739 2,702 1% 5,221 5,182 1% Research and development 3,500 13,321 -74% 7,492 17,597 -57% Restructuring costs 80 151 -47% 202 218 -7% Other (income) expense, net 42 172 -76% 12 259 -95% Income (Loss) Before Taxes 6,006 (5,335) * 11,675 (1,685) * Income Tax Provision 545 637 1,447 1,462 Net Income (Loss) 5,461 (5,972) * 10,228 (3,147) * Less: Net Income Attributable to Noncontrolling Interests 6 3 11 7 Net Income (Loss) Attributable to Merck & Co., Inc. 5,455 $ (5,975) $ * 10,217 $ (3,154) $ * Earnings (Loss) per Common Share Assuming Dilution (1) 2.14 $ (2.35) $ * 4.02 $ (1.24) $ * Average Shares Outstanding Assuming Dilution (1) 2,544 2,539 2,544 2,539 Tax Rate 9.1% -11.9% 12.4% -86.8% * 100% or greater MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 (1) Because the company recorded a net loss in the second quarter and first six months of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. GAAP % Change 2Q24 2Q23 GAAP % Change June YTD 2024 June YTD 2023 2 -- 3 of 10 -- Second Quarter Cost of sales 3,745 $ 606 66 672 3,073 $ Selling, general and administrative 2,739 24 31 55 2,684 Research and development 3,500 20 20 3,480 Restructuring costs 80 80 80 – Other (income) expense, net 42 (17) (49) (66) 108 Income Before Taxes 6,006 (633) (177) 49 (761) 6,767 Income Tax Provision (Benefit) 545 (129) (3) (30) (3) 11 (3) (259) (4) (407) 952 Net Income 5,461 (504) (147) 38 259 (354) 5,815 Net Income Attributable to Merck & Co., Inc. 5,455 (504) (147) 38 259 (354) 5,809 Earnings per Common Share Assuming Dilution 2.14 $ (0.20) (0.06) 0.02 0.10 (0.14) 2.28 $ Tax Rate 9.1% 14.1% June YTD Cost of sales 7,285 $ 1,069 182 1,251 6,034 $ Selling, general and administrative 5,221 45 36 81 5,140 Research and development 7,492 36 2 38 7,454 Restructuring costs 202 202 202 – Other (income) expense, net 12 (21) (165) (186) 198 Income Before Taxes 11,675 (1,129) (422) 165 (1,386) 13,061 Income Tax Provision (Benefit) 1,447 (221) (3) (72) (3) 36 (3) (259) (4) (516) 1,963 Net Income 10,228 (908) (350) 129 259 (870) 11,098 Net Income Attributable to Merck & Co., Inc. 10,217 (908) (350) 129 259 (870) 11,087 Earnings per Common Share Assuming Dilution 4.02 $ (0.35) (0.14) 0.05 0.10 (0.34) 4.36 $ Tax Rate 12.4% 15.0% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. THREE AND SIX MONTHS ENDED JUNE 30, 2024 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a (4) Represents a benefit due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year. Adjustment Subtotal Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items 3 -- 4 of 10 -- Second Quarter Cost of sales 4,024 $ 467 32 499 3,525 $ Selling, general and administrative 2,702 25 52 77 2,625 Research and development 13,321 9 1 10 13,311 Restructuring costs 151 151 151 - Other (income) expense, net 172 (3) 194 191 (19) Loss Before Taxes (5,335) (498) (236) (194) (928) (4,407) Income Tax Provision (Benefit) 637 (91) (4) (38) (4) (44) (4) (173) 810 Net Loss (5,972) (407) (198) (150) (755) (5,217) Net Loss Attributable to Merck & Co., Inc. (5,975) (407) (198) (150) (755) (5,220) Loss per Common Share Assuming Dilution (5) (2.35) $ (0.16) (0.07) (0.06) (0.29) (2.06) $ Tax Rate -11.9% -18.4% June YTD Cost of sales 7,951 $ 1,012 61 1,073 6,878 $ Selling, general and administrative 5,182 45 53 98 5,084 Research and development 17,597 19 1 20 17,577 Restructuring costs 218 218 218 - Other (income) expense, net 259 12 (235) 573 (3) 350 (91) (Loss) Income Before Taxes (1,685) (1,088) (333) 235 (573) (1,759) 74 Income Tax Provision (Benefit) 1,462 (196) (4) (56) (4) 51 (4) (60) (4) (261) 1,723 Net Loss (3,147) (892) (277) 184 (513) (1,498) (1,649) Net Loss Attributable to Merck & Co., Inc. (3,154) (892) (277) 184 (513) (1,498) (1,656) Loss per Common Share Assuming Dilution (5) (1.24) $ (0.35) (0.11) 0.07 (0.20) (0.59) (0.65) $ Tax Rate -86.8% 2,328.4% Only the line items that are affected by non-GAAP adjustments are shown. (5) Because the company recorded a net loss in the second quarter and first six months of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the six-month period primarily reflect a $37 million loss on the sale of a business and an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture, partially offset by royalty income. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation. (4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Adjustment Subtotal Non-GAAP MERCK & CO., INC. THREE AND SIX MONTHS ENDED JUNE 30, 2023 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items 4 -- 5 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2024 2023 2Q June YTD 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $15,775 $16,112 $31,887 $14,487 $15,035 $29,522 $15,962 $14,630 $60,115 7 11 8 11 PHARMACEUTICAL 14,006 14,408 28,415 12,721 13,457 26,179 14,263 13,141 53,583 7 11 9 12 Oncology Keytruda 6,947 7,270 14,217 5,795 6,271 12,065 6,338 6,608 25,011 16 21 18 22 Alliance Revenue – Lynparza (2) 292 317 609 275 310 585 299 315 1,199 2 4 4 6 Alliance Revenue – Lenvima (2) 255 249 504 232 242 474 260 226 960 3 4 6 7 Welireg 85 126 211 42 50 92 54 72 218 150 150 128 128 Alliance Revenue – Reblozyl (3) 71 90 161 43 47 90 52 70 212 92 92 80 80 Vaccines (4) Gardasil/Gardasil 9 2,249 2,478 4,727 1,972 2,458 4,430 2,585 1,871 8,886 1 4 7 10 ProQuad/M-M-R II/Varivax 570 617 1,187 528 582 1,109 713 545 2,368 6 7 7 7 Vaxneuvance 219 189 408 106 168 274 214 176 665 13 16 49 51 RotaTeq 216 163 379 297 131 428 156 185 769 25 26 -11 -10 Pneumovax 23 61 59 120 96 92 188 140 85 412 -36 -32 -36 -32 Hospital Acute Care Bridion 440 455 895 487 502 989 424 429 1,842 -9 -8 -9 -8 Prevymis 174 188 362 129 143 273 157 175 605 31 35 33 37 Dificid 73 92 165 65 76 141 74 87 302 20 20 16 16 Zerbaxa 56 62 118 50 54 104 53 61 218 14 18 13 16 Noxafil 56 45 101 60 55 116 51 46 213 -20 -9 -13 -2 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 98 106 203 99 68 167 92 108 367 56 56 22 22 Adempas (6) 70 72 142 59 65 125 65 66 255 11 15 14 17 Winrevair 70 70 - - - - Virology Lagevrio 350 110 460 392 203 595 640 193 1,428 -46 -42 -23 -18 Isentress/Isentress HD 111 89 200 123 136 259 119 105 483 -35 -31 -23 -19 Delstrigo 56 60 116 44 50 94 54 54 201 19 23 23 26 Pifeltro 42 39 81 34 38 72 37 33 142 3 4 13 13 Neuroscience Belsomra 46 53 99 56 63 119 58 54 231 -16 -8 -17 -10 Immunology Simponi 184 172 356 180 180 359 179 171 710 -4 -2 -1 -1 Remicade 39 35 74 51 48 99 45 43 187 -27 -20 -25 -21 Diabetes (7) Januvia 419 405 824 551 511 1,062 581 547 2,189 -21 -16 -22 -19 Janumet 251 224 475 329 354 683 255 240 1,177 -37 -32 -30 -26 Other Pharmaceutical (8) 576 573 1,151 626 560 1,187 568 576 2,333 2 6 -3 -1 ANIMAL HEALTH 1,511 1,482 2,993 1,491 1,456 2,947 1,400 1,278 5,625 2 6 2 5 Livestock 850 837 1,686 849 807 1,656 874 808 3,337 4 11 2 7 Companion Animal 661 645 1,307 642 649 1,291 526 470 2,288 -1 1 1 3 Other Revenues (9) 258 222 479 275 122 396 299 211 907 82 53 21 24 Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (7) Total Diabetes sales were $745 million and $715 million in the first and second quarter of 2024, respectively, and $950 million and $951 million in the first and second quarter of 2023, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $61 million and $15 million in the first and second quarter of 2024, respectively, and $51 million and $3 million in the first and second quarter of 2023, respectively. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $3,424 million and $3,656 million in the first and second quarter of 2024, respectively, and $3,133 million and $3,557 million in the first and second quarter of 2023, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. 5 -- 6 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES SECOND QUARTER 2024 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 2Q 2024 2Q 2023 % Change 2Q 2024 2Q 2023 % Change 2Q 2024 2Q 2023 % Change TOTAL SALES (1) $16,112 $15,035 7 $7,876 $7,018 12 $8,236 $8,018 3 PHARMACEUTICAL 14,408 13,457 7 7,399 6,570 13 7,009 6,887 2 Oncology Keytruda 7,270 6,271 16 4,412 3,863 14 2,858 2,408 19 Alliance Revenue – Lynparza (2) 317 310 2 153 144 6 165 166 -1 Alliance Revenue – Lenvima (2) 249 242 3 177 163 8 73 79 -7 Welireg 126 50 150 116 49 138 10 2 * Alliance Revenue – Reblozyl (3) 90 47 92 75 36 110 15 11 36 Vaccines (4) Gardasil/Gardasil 9 2,478 2,458 1 536 464 16 1,941 1,994 -3 ProQuad/M-M-R II/Varivax 617 582 6 490 447 10 127 135 -6 Vaxneuvance 189 168 13 99 147 -33 90 20 * RotaTeq 163 131 25 107 93 15 56 37 50 Pneumovax 23 59 92 -36 11 23 -54 48 69 -30 Hospital Acute Care Bridion 455 502 -9 351 299 17 104 203 -49 Prevymis 188 143 31 90 61 47 98 82 19 Dificid 92 76 20 79 68 16 12 8 56 Zerbaxa 62 54 14 33 30 12 28 24 17 Noxafil 45 55 -20 11 N/M 44 45 -1 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 106 68 56 98 70 41 8 -2 * Adempas (6) 72 65 11 72 65 11 Winrevair 70 - 70 - Virology Lagevrio 110 203 -46 15 2 * 95 201 -53 Isentress/Isentress HD 89 136 -35 43 56 -24 46 80 -42 Delstrigo 60 50 19 14 13 13 45 37 21 Pifeltro 39 38 3 27 27 -1 12 11 15 Neuroscience Belsomra 53 63 -16 19 21 -12 34 42 -18 Immunology Simponi 172 180 -4 172 180 -4 Remicade 35 48 -27 35 48 -27 Diabetes (7) Januvia 405 511 -21 177 243 -27 227 267 -15 Janumet 224 354 -37 17 82 -80 208 272 -24 Other Pharmaceutical (8) 573 560 2 190 158 20 386 403 -4 ANIMAL HEALTH 1,482 1,456 2 455 475 -4 1,027 982 5 Livestock 837 807 4 168 165 2 669 643 4 Companion Animal 645 649 -1 287 310 -7 358 339 6 Other Revenues (9) 222 122 82 22 -27 -181 200 149 34 *200% or greater N/M - Not Meaningful (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $715 million in the second quarter of 2024, and $951 million in the second quarter of 2023. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $15 million in the second quarter of 2024 and $3 million in the second quarter of 2023. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $3,656 million in the second quarter of 2024 and $3,557 million in the second quarter of 2023. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International June YTD 2024 June YTD 2023 % Change June YTD 2024 June YTD 2023 % Change June YTD 2024 June YTD 2023 % Change TOTAL SALES (1) $31,887 $29,522 8 $15,354 $13,676 12 $16,533 $15,846 4 PHARMACEUTICAL 28,415 26,179 9 14,336 12,688 13 14,079 13,491 4 Oncology Keytruda 14,217 12,065 18 8,531 7,348 16 5,686 4,718 21 Alliance Revenue – Lynparza (2) 609 585 4 288 286 1 321 299 7 Alliance Revenue – Lenvima (2) 504 474 6 349 316 10 155 158 -2 Welireg 211 92 128 194 90 116 17 3 * Alliance Revenue – Reblozyl (3) 161 90 80 133 66 102 28 24 17 Vaccines (4) Gardasil/Gardasil 9 4,727 4,430 7 1,024 880 16 3,702 3,550 4 ProQuad/M-M-R II/Varivax 1,187 1,109 7 928 868 7 259 242 7 Vaxneuvance 408 274 49 260 241 8 148 33 * RotaTeq 379 428 -11 257 273 -6 123 155 -21 Pneumovax 23 120 188 -36 17 63 -73 103 125 -17 Hospital Acute Care Bridion 895 989 -9 680 576 18 215 413 -48 Prevymis 362 273 33 165 116 42 197 157 26 Dificid 165 141 16 147 130 13 17 11 54 Zerbaxa 118 104 13 67 57 17 51 47 9 Noxafil 101 116 -13 8 25 -67 92 91 2 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 203 167 22 188 153 23 16 14 11 Adempas (6) 142 125 14 142 125 14 Winrevair 70 - 70 - Virology Lagevrio 460 595 -23 60 - 400 595 -33 Isentress/Isentress HD 200 259 -23 93 108 -14 107 151 -29 Delstrigo 116 94 23 26 24 11 89 70 27 Pifeltro 81 72 13 56 51 9 25 21 20 Neuroscience Belsomra 99 119 -17 33 37 -10 66 82 -19 Immunology Simponi 356 359 -1 356 359 -1 Remicade 74 99 -25 74 99 -25 Diabetes (7) Januvia 824 1,062 -22 361 514 -30 463 548 -15 Janumet 475 683 -30 55 138 -60 420 544 -23 Other Pharmaceutical (8) 1,151 1,187 -3 346 328 5 807 857 -6 ANIMAL HEALTH 2,993 2,947 2 929 956 -3 2,064 1,991 4 Livestock 1,686 1,656 2 334 338 -1 1,352 1,318 3 Companion Animal 1,307 1,291 1 595 618 -4 712 673 6 Other Revenues (9) 479 396 21 89 32 178 390 364 7 *200% or greater (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $1,461 million and $1,901 million on a global basis for June YTD 2024 and 2023, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $76 million and $54 million on a global basis for June YTD 2024 and 2023, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $7,080 million and $6,690 million on a global basis for June YTD 2024 and 2023, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 7 -- 8 of 10 -- # MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 2024 2023 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD TOTAL PHARMACEUTICAL $14,006 $14,408 $28,415 $12,721 $13,457 $26,179 $14,263 $13,141 $53,583 7 9 United States 6,936 7,399 14,336 6,117 6,570 12,688 7,153 6,698 26,539 13 13 % Pharmaceutical Sales 49.5% 51.4% 50.5% 48.1% 48.8% 48.5% 50.1% 51.0% 49.5% Europe (1) 2,555 2,572 5,128 2,326 2,401 4,727 2,497 2,491 9,715 7 8 % Pharmaceutical Sales 18.2% 17.9% 18.0% 18.3% 17.8% 18.1% 17.5% 19.0% 18.1% China 1,744 1,790 3,534 1,694 1,887 3,581 1,674 1,456 6,710 -5 -1 % Pharmaceutical Sales 12.5% 12.4% 12.4% 13.3% 14.0% 13.7% 11.7% 11.1% 12.5% Japan 802 664 1,466 737 652 1,390 1,062 629 3,081 2 6 % Pharmaceutical Sales 5.7% 4.6% 5.2% 5.8% 4.8% 5.3% 7.4% 4.8% 5.7% Latin America 601 661 1,262 470 566 1,036 696 596 2,328 17 22 % Pharmaceutical Sales 4.3% 4.6% 4.4% 3.7% 4.2% 4.0% 4.9% 4.5% 4.3% Asia Pacific (other than China and Japan) 580 595 1,175 703 705 1,409 636 616 2,661 -16 -17 % Pharmaceutical Sales 4.1% 4.1% 4.1% 5.5% 5.2% 5.4% 4.5% 4.7% 5.0% Eastern Europe/Middle East/Africa 395 353 747 381 370 751 301 299 1,351 -5 -1 % Pharmaceutical Sales 2.8% 2.4% 2.6% 3.0% 2.7% 2.9% 2.1% 2.3% 2.5% Canada 138 143 281 141 127 268 133 138 540 12 5 % Pharmaceutical Sales 1.0% 1.0% 1.0% 1.1% 0.9% 1.0% 0.9% 1.1% 1.0% Other 255 231 486 152 179 329 111 218 658 29 48 % Pharmaceutical Sales 1.9% 1.6% 1.8% 1.2% 1.6% 1.1% 0.9% 1.5% 1.4% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 2Q24 2Q23 June YTD 2024 June YTD 2023 Interest income (69) $ (109) $ (141) $ (221) $ Interest expense 310 277 613 519 Exchange losses 60 62 144 122 (Income) loss from investments in equity securities, net (1) (56) 175 (200) (274) Net periodic defined benefit plan (credit) cost other than service cost (159) (111) (319) (226) Other, net (44) (122) (85) 339 Total 42 $ 172 $ 12 $ 259 $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --